Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients

被引：0
|
作者：
Shen, Jingyi [1 ,2 ]
Shan, Meng [1 ,2 ]
Chu, Mengqian [1 ,2 ]
Cai, Yiming [1 ,2 ]
Rui, Jingwen [1 ,2 ]
Chen, Suning [1 ,2 ]
Wu, Depei [1 ,2 ]
Xu, Yang [1 ,2 ]
机构：
[1] Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
来源：
BLOOD CANCER JOURNAL | 2025年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
MUTATIONS; CBFB-MYH11; KIT; AML;
D O I：
10.1038/s41408-025-01227-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Decitabine Versus Intensive Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Choi, Eun-Ji
    Lee, Je-Hwan
    Park, Han-Seung
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Woo, Ji Min
    Lee, Kyoo Hyung
    BLOOD, 2018, 132
  • [22] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
    Dian Jin
    Haoguang Chen
    Jingsong He
    Yi Li
    Gaofeng Zheng
    Yang Yang
    Yi Zhao
    Jing Le
    Wenxiu Shu
    Donghua He
    Zhen Cai
    Targeted Oncology, 2024, 19 : 237 - 249
  • [23] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
    Jin, Dian
    Chen, Haoguang
    He, Jingsong
    Li, Yi
    Zheng, Gaofeng
    Yang, Yang
    Zhao, Yi
    Le, Jing
    Shu, Wenxiu
    He, Donghua
    Cai, Zhen
    TARGETED ONCOLOGY, 2024, 19 (02) : 237 - 249
  • [24] Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun Vinod
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD ADVANCES, 2022, 6 (17) : 5227 - 5231
  • [25] Intensive Induction Chemotherapy Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Schaefer, Eva Johanna
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Lindsley, Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony Selwyn
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Ball, Brian J.
    Stahl, Maximilian
    BLOOD, 2023, 142
  • [26] Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification
    Wan, Chao-Ling
    Liu, Yu-Qing
    Liu, Fang-Tong
    Huang, Yuan-Hong
    Cao, Han-Yu
    Huang, Si-Man
    Tan, Kai-Wen
    Ge, Shuai-Shuai
    Wang, Miao
    Liu, Mei-Jing
    Wang, Zi-Hao
    Li, Zheng
    Xue, Sheng-Li
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [27] Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country
    Mirgh, Sumeet
    Sharma, Archana
    Shaikh, Mohammad Rizwan Mohammad Anwar
    Kadian, Kirti
    Agrawal, Narendra
    Khushoo, Vishvdeep
    Mehta, Pallavi
    Ahmed, Rayaz
    Bhurani, Dinesh
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2021, 11 (03): : 290 - 302
  • [28] Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
    Weiss, Julian J.
    Yates, Samuel J.
    Badar, Talha
    Patel, Anand Ashwin
    Winer, Eric S.
    Litzow, Mark R.
    Cheng, Wei
    Lin, Chenyu
    Shallis, Rory M.
    BLOOD, 2024, 144 : 1489 - 1490
  • [29] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Yao Qin
    Pu Kuang
    Ting Liu
    Clinical and Experimental Medicine, 2023, 23 : 219 - 227
  • [30] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Qin, Yao
    Kuang, Pu
    Liu, Ting
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 219 - 227
12345